Determinants of the Over-Anticoagulation Response during Warfarin Initiation Therapy in Asian Patients Based on Population Pharmacokinetic-Pharmacodynamic Analyses

Abstract

To clarify pharmacokinetic-pharmacodynamic (PK-PD) factors associated with the over-anticoagulation response in Asians during warfarin induction therapy, population PK-PD analyses were conducted in an attempt to predict the time-courses of the plasma S-warfarin concentration, Cp(S), and coagulation and anti-coagulation (INR) responses. In 99 Chinese patients we analyzed the relationships between dose and Cp(S) to estimate the clearance of S-warfarin, CL(S), and that between Cp(S) and the normal prothrombin concentration (NPT) as a coagulation marker for estimation of IC50. We also analyzed the non-linear relationship between NPT inhibition and the increase in INR to derive the non-linear index λ. Population analyses accurately predicted the time-courses of Cp(S), NPT and INR. Multivariate analysis showed that CYP2C9*3 mutation and body surface area were predictors of CL(S), that VKORC1 and CYP4F2 polymorphisms were predictors of IC50, and that baseline NPT was a predictor of λ. CL(S) and λ were significantly lower in patients with INR≥4 than in those with INR<4 (190 mL/h vs 265 mL/h, P<0.01 and 3.2 vs 3.7, P<0.01, respectively). Finally, logistic regression analysis revealed that CL(S), ALT and hypertension contributed significantly to INR≥4. All these results indicate that factors associated with the reduced metabolic activity of warfarin represented by CL(S), might be critical determinants of the over-anticoagulation response during warfarin initiation in Asians.Trial RegistrationClinicalTrials.gov NCT02065388

Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children

“…This does not exclude the possibility that each patient may have an optimal target concentration and benefit from dose individualization . Second, DDIs can cause significant changes in the systemic exposure to first line drugs, and this also applies for many add‐on drugs in a combination . In theory, this implies that the observed treatment response, or lack thereof, cannot be directly attributed to the add‐on drug.…”

A multi-factorial analysis of response to warfarin in a UK prospective cohort

“…The regulation of clotting factors is most probably complex and the genetic variants involved in such processes are likely to have a low to moderate impact on warfarin response (below 5 % for mean dosing), and thus are unlikely to be included in dosing algorithms unless whole genome sequencing data become incorporated into patient records. Curiously, while ALT was found to contribute significantly to over-anticoagulation during warfarin initiation in a cohort of patients from Asian descent, it was not significant in our INR >4 analysis [ 43 ]. It was found to be significantly associated with MWD in our univariate regressions, but was not retained in the final model.…”

Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients

“…Because there were no observations during the absorption phase, the absorption half‐life was fixed to a value of 0.385 h corresponding to a first‐order absorption rate constant of 1.8 h −1 . Other values (ranging from 1.6–2.0 h −1 ) were also tested according to previous reports but did not obviously improve the fit .…”

“…Modeling techniques can be valuable tools for individual dose predictions for drugs with considerable variability in individual requirements, including selection of the optimal initial dose and adjustment of subsequent doses . Several studies of warfarin pharmacokinetics (PK) and pharmacodynamics (PD) models have been reported, but most have focused on mixed disease populations, such as patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism or healthy volunteers . No reported studies have specifically focused on cardiac surgery patients.…”